Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients-中国Betway体育网页登陆

摘要 AIM:ToinvestigatewhethertheevaluationoftumorbuddingcancomplementK-RASanalysistoimprovetheindividualizedpredictionofresponsetoanti-epidermalgrowthfactorreceptorbasedtherapiesinmetastaticcolorectalcancer(mCRC)patients.METHODS:Forty-threepatientswithmCRCtreatedwithcetuximaborpanitumumabwereenteredintothisstudy.AccordingtotheResponseEvaluationCriteriainSolidTumorscriteria,30patientshadstableorprogressivedisease(non-responsive),while13patientshadapartialresponse.Tumorbudswereevaluatedfromwholetissuesectionsstainedforpan-cytokeratin,evaluatedinthedensestregionusinga40×objectiveand'high-grade'tumorbuddingwasdefinedas15buds/high-powerfield.RESULTS:TumorbudsandK-RASmutationbothcorrectlyclassified68%ofpatients.AllpatientswithK-RASmutation(n=7)orhigh-gradetumorbudding(n=11)werenon-responsive,ofwhich4patientshadbothfeatures.All13partialresponderswereK-RASwild-typewithlow-gradetumorbudding.Combined,thepredictivevalueofK-RASandtumorbuddingwas80%.Additionally,high-gradetumorbuddingwassignificantlyrelatedtoworseprogression-freesurvival[HR(95%CI):2.8(1.3-6.0,P=0.008)].CONCLUSION:Ifconfirmedinlargercohorts,theadditionoftumorbuddingtoK-RASanalysismayrepresentaneffectiveapproachforindividualizedpatientmanagementinthemetastaticsetting.

1Wei-Dong Shen;Hong-Lin Chen;Peng-Fei Liu.EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment： a meta-analysis.肿瘤,2014-01.
2Gonzalo Tapia Rico;Timothy J. Price;Christos Karapetis;Cynthia Piantadosi;Rob Padbury;Amitesh Roy;Guy Maddern;James Moore;Scott Carruthers;David Roder;Amanda R. Townsend.Brain metastasis in advanced colorectal cancer： results from the South Australian metastatic colorectal cancer （SAmCRC） registry.肿瘤,2017-04.
3Dai Hongmei,Hong Xiafei,Huang Dan,Wu Huanwen,Wang Xianze,Chen Hao,Jiang Rui,Chen Wenyan,Zhao Yupei,Wu Wenming.Notch signaling inhibitor and anti-PD-L1 antibody combination therapies decelerate tumor progression in pancreatic cancer.医药卫生,2021-09.
4Yu-Yuan Li; Quan-Xing Ge; Jie Cao; Yong-Jian Zhou; Yan-Lei Du; Bo Shen; Yu-Jui Yvonne Wan; Yu-Qiang Nie.Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients.消化系统,2016-11.
5Markus Moehler;Martin F Sprinzl;Murad Abdelfattah;Carl C Schimanski;Bernd Adami;Werner Godderz;Klaus Majer;Dimitri Flieger;Andreas Teufel;Juergen Siebler;Thomas Hoehler;Peter R Galle;Stephan Kanzler.Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients.消化系统,2009-04.
6Hongnan Mo,Fei Ma,Qing Li,Pin Zhang,Peng Yuan,Jiayu Wang,Yang Luo,Ruigang Cai,Qiao Li,Binghe Xu.Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.医药卫生,2022-12.
7Liem Minh Phan;Sai-Ching Jim yeung;Mong-Hong Lee.Cancer metabolic reprogramming： importance, main features, and potentials for precise targeted anti-cancer therapies.肿瘤,2014-01.
8Junling Liu.Retrospective analysis of patients with rare-site and metastatic giant cell tumor.肿瘤,2013-05.
9Mohamed A.Daoud;Engy M.Aboelnaga;Wael M.Mohamed.Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer：a single-institution experience.肿瘤,2016-01.
10Mariacarmela Santarpia2;Niki Karachaliou.Tumor immune microenvironment characterization and response to anti-PD-1 therapy.肿瘤,2015-02.

Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients

来源期刊

相关推荐

同分类资源更多

相关关键词